NAVERIS Revenue and Competitors

Natick, MA

Location

#9292

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • NAVERIS's estimated annual revenue is currently $13.2M per year.(i)
  • NAVERIS's estimated revenue per employee is $155,000
  • NAVERIS's total funding is $51M.

Employee Data

  • NAVERIS has 85 Employees.(i)
  • NAVERIS grew their employee count by 20% last year.

NAVERIS's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Founder & CEOReveal Email/Phone
3
Chief Staff to the CEOReveal Email/Phone
4
Chief Clinical OperationsReveal Email/Phone
5
SVP Commercial OperationsReveal Email/Phone
6
VP Market AccessReveal Email/Phone
7
VP Finance, MBA, CPAReveal Email/Phone
8
SVP, Finance & Business OperationsReveal Email/Phone
9
Head Recruiting OperationsReveal Email/Phone
10
Director Sales and Product DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is NAVERIS?

Our mission at NAVERIS is to deliver innovations in technology with the potential to transform cancer detection, drug development, and clinical trials. Early detection of malignant cancers is critical to ensuring that tumors can be effectively treated with a favorable prognosis for patients. To this end, we are developing several related technologies with the potential to offer highly sensitive and specific cancer detection through blood analysis. Our flagship technology is a liquid biopsy blood test that analyzes tumor DNA in the circulation to detect specific subtypes of cancer. In clinical studies, this test has established its ability to detect cancers early – in many cases months before patients would be symptomatic given current clinical practice. Complementing these efforts, we are also leveraging innovations in 3D biomimetic technology to provide more accurate ex vivo models for every stage of drug development – ranging from target ID & HTS to lead optimization & validation. Our 3D biomimetic technology replicates the morphological, signaling and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, our technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.

keywords:N/A

$51M

Total Funding

85

Number of Employees

$13.2M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NAVERIS News

2022-02-22 - Naveris' Head and Neck Cancer Recurrence Detection Study ...

Naveris' first commercial-stage diagnostic, NavDx®, is a blood test that supports the clinical management of patients with HPV-driven cancers.

2022-02-22 - Sprinter Health and Naveris collaborate on NavDx testing

February 3, 2022 -- At-home lab services company Sprinter Health and molecular diagnostics firm Naveris have established a partnership to streamline patient...

2022-02-22 - Sprinter Health and Naveris Partner to Expand Access to NavDx ...

Naveris' flagship diagnostic, NavDx®, is a blood test that supports the clinical management of patients with HPV-driven cancers. Since its...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.1M9360%N/A
#2
$15.2M98-17%$65.9M
#3
$15M10011%N/A
#4
$23.4M1037%N/A
#5
$24.3M1072%N/A